Starting January 1, 2021, Eli Lilly and Company (NYSE:LLY) will reduce the list price of Insulin Lispro Injection in the U.S. to match 2008 levels. The 40% price cut will also extend to the company’s non-branded insulins. Still, the company acknowledged that people with fixed insurance co-pays or beneficiaries of Lilly’s affordability programs might not…